<?xml version="1.0" standalone="no"?>
<!DOCTYPE ALGORITHM SYSTEM 
  "http://hivdb2.stanford.edu/asi/xml/ASI.dtd">

<ALGORITHM>
    <ALGNAME>HIVDB</ALGNAME>
    <ALGVERSION>4.3.6</ALGVERSION>

    <PROCESSING_DIRECTIVES>
	<SHOW_ATYPICAL_MUTATIONS/>
        <RESTRICTED_POSITION_SCORING/>
    </PROCESSING_DIRECTIVES>

    <DEFINITIONS>
    	
    	<GENE_DEFINITION>
    		<NAME>RT</NAME>
    		<DRUGCLASSLIST>NNRTI</DRUGCLASSLIST>
    	</GENE_DEFINITION>
    	<GENE_DEFINITION>
    		<NAME>PR</NAME>
    	</GENE_DEFINITION>
   
        <LEVEL_DEFINITION>
            <ORDER>1</ORDER>
            <ORIGINAL>Susceptible</ORIGINAL>
            <SIR>S</SIR>
        </LEVEL_DEFINITION>

        <LEVEL_DEFINITION>
            <ORDER>2</ORDER>
            <ORIGINAL>Potential low-level resistance</ORIGINAL>
            <SIR>S</SIR>
        </LEVEL_DEFINITION>

        <LEVEL_DEFINITION>
            <ORDER>3</ORDER>
            <ORIGINAL>Low-level resistance</ORIGINAL>
            <SIR>I</SIR>
        </LEVEL_DEFINITION>

        <LEVEL_DEFINITION>
            <ORDER>4</ORDER>
            <ORIGINAL>Intermediate resistance</ORIGINAL>
            <SIR>I</SIR>
        </LEVEL_DEFINITION>

        <LEVEL_DEFINITION>
            <ORDER>5</ORDER>
            <ORIGINAL>High-level resistance</ORIGINAL>
            <SIR>R</SIR>
        </LEVEL_DEFINITION>
  
        <DRUGCLASS>
            <NAME>PI</NAME>
            <DRUGLIST>FPV,IDV,LPV,NFV,SQV,ATV,TPV,DRV</DRUGLIST>
        </DRUGCLASS>

        <DRUGCLASS>
            <NAME>NRTI</NAME>
            <DRUGLIST>AZT,D4T,DDI,3TC,FTC,ABC,TDF</DRUGLIST>
        </DRUGCLASS>

        <DRUGCLASS>
            <NAME>NNRTI</NAME>
            <DRUGLIST>NVP,DLV,EFV,ETR</DRUGLIST>
        </DRUGCLASS>

        <GLOBALRANGE>
            (-INF TO 10     => 1, 
             11 TO 15   => 2, 
             16 TO 30   => 3,
             31 TO 60   => 4,
             61 TO INF  => 5)
        </GLOBALRANGE>

	<COMMENT_DEFINITIONS>
	    <COMMENT_STRING id="PR1">
		<TEXT>The following $numberOfMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} of the 11 darunavir POWER/DUET study mutations were present: $listMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} (DeMeyer S et al, EHDRW 2008).
                </TEXT>
		<SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

	    <COMMENT_STRING id="PR2">
		<TEXT>This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}).  RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007).
                </TEXT>
		<SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT3">
                <TEXT>$listHitsAt{74} partially reverses AZT and possibly d4T resistance caused by other mutations. AZT mutations in this isolate include: $listHitsAt{41,67,70,210,215,219}.
                </TEXT>
		<SORT_TAG>2</SORT_TAG>
            </COMMENT_STRING>
	
	    <COMMENT_STRING id="RT4">
                <TEXT>$listHitsAt{184} partially reverses AZT, d4T, and TDF resistance caused by other AZT mutations (TAMs). AZT mutations in this isolate include: $listHitsAt{41,67,70,210,215,219}.
                </TEXT>
		<SORT_TAG>2</SORT_TAG>
            </COMMENT_STRING>

	    <COMMENT_STRING id="RT5">
                <TEXT>$listHitsAt{100} partially reverses AZT and possibly d4T resistance caused by other mutations. AZT mutations in this isolate include: $listHitsAt{41,67,70,210,215,219}.
                </TEXT>
		<SORT_TAG>2</SORT_TAG>
            </COMMENT_STRING>

	    <COMMENT_STRING id="RT6">
                <TEXT>$listHitsAt{181} partially reverses AZT and possibly d4T resistance caused by other mutations. AZT mutations in this isolate include: $listHitsAt{41,67,70,210,215,219}.
                </TEXT>
		<SORT_TAG>2</SORT_TAG>
            </COMMENT_STRING>

	    <COMMENT_STRING id="RT7">
                <TEXT>The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007).
                </TEXT>
		<SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

<!-- Begin the PR mutation-dependent comment strings. -->
            <COMMENT_STRING id="PR_POS10">
                <TEXT>L10I/V/F/R are associated with resistance to each of the PIs when present with other mutations. L10I/V occur commonly in 5-10% of untreated persons. L10FRY are nonpolymorphic.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS11">
                <TEXT>V11I is a nonpolymorphic accessory mutation weakly associated with PI therapy. It is one of the 11 mutations associated with decreased response to DRV in the POWER trials.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS13">
                <TEXT>I13V is a common polymorphism that is slightly more common in treated compared with untreated subtype B isolates. In subtypes A, AE, AG, and G it is the consensus residue. I13V was weakly associated with decreased virological response to TPV in the RESIST trials.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS16">
                <TEXT>G16E is a highly polymorphic mutation occurring in 2% to 20% of viruses depending on subtype. It may be weakly associated with ATV therapy and response.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS20">
                <TEXT>K20R/M/I/T are weakly associated with resistance to each of the PIs when present with other mutations. Many variants at this position occur commonly in non-subtype B viruses.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS23">
                <TEXT>L23I is a rare substrate cleft mutation that causes low-level resistance to NFV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS24F">
                <TEXT>L24F is a rare mutation at this position; its phenotypic effect is not known.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS24I">
                <TEXT>L24I is associated with reduced susceptibility to IDV and possibly RTV, LPV, SQV, and ATV when present with other mutations.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS30">
                <TEXT>D30N causes intermediate resistance to NFV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS32">
                <TEXT>V32I is a substrate cleft mutation that reduces susceptibility to IDV, RTV, FPV, LPV, TPV, and DRV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS33F">
                <TEXT>L33F are selected by FPV, DRV, LPV, ATV, and TPV, and slightly contribute resistance to these drugs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS33I">
                <TEXT>L33F are selected by FPV, DRV, LPV, ATV, and TPV, and slightly contribute resistance to these drugs. L33I is less common than L33F but may have a similar effect.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS33V">
                <TEXT>L33V is a polymorphism that does not appear to be related to PI therapy or drug resistance.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS35">
                <TEXT>E35G is a nonpolymorphic mutation that is slightly more common in viruses from PI-treated (particularly NFV-treated) compared with untreated persons. It was weakly associated a decreased virological response to TPV in the RESIST trials.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS36">
                <TEXT>M36I/V are weakly associated with PI resistance when present with other mutations. M36I occurs commonly in certain non-subtype B viruses. M36L/T are rare variants of uncertain significance.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS43">
                <TEXT>K43T is a nonpolymorphic mutation that is significantly more common in viruses from PI-treated compared with untreated persons. It was weakly associated with a decreased virological response to TPV in the RESIST trials.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS46IL">
                <TEXT>M46I/L decreases susceptibility to IDV, NFV, FPV, LPV, ATV, TPV, and possibly SQV and DRV when present with other mutations.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS46V">
                <TEXT>M46I/L decreases susceptibility to IDV, NFV, FPV, LPV, ATV, TPV, and possibly SQV and DRV when present with other mutations. M46V is a rare mutation at this position of uncertain significance.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS47A">
                <TEXT>I47A usually occurs in combination with V32I and in this setting causes high-level LPV and FPV resistance and probably intermediate DRV resistance.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS47V">
                <TEXT>I47V decrease susceptibility to FPV, ATV, IDV, LPV, TPV, and DRV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS48M">
                <TEXT>G48M causes high-level SQV resistance and intermediate resistance to NFV, ATV, IDV, and NFV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS48V">
                <TEXT>G48V causes high-level SQV resistance, intermediate ATV and NFV resistance, and low-level IDV and LPV resistance.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS50L">
                <TEXT>I50L causes intermediate-to-high level resistance to ATV and hypersusceptibility to the remaining PIs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS50V">
                <TEXT>I50V causes intermediate-to-high-level resistance to FPV, intermediate resistance to LPV and DRV, and increased susceptibility to TPV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS53">
                <TEXT>F53L occurs only in isolates from treated patients nearly always in combinations with other PI-resistance mutations. It is associated with decreased susceptibility to IDV, LPV, and SQV and possibly other PIs. F53Y is a rare treatment-associated variant.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS54ATS">
                <TEXT>I54T/A/S are PI-related mutations typically observed in heavily treated persons and like I54V and I54M/L are likely to reduce susceptibility to most PIs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS54L">
                <TEXT>I54L occurs in patients receiving FPV, LPV, and DRV and reduces susceptibility to these drugs and to NFV and possibly ATV. It is associated with increased susceptibility to TPV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS54M">
                <TEXT>I54M occurs in patients receiving FPV, LPV, and DRV and reduces susceptibility to these drugs and to ATV and NFV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS54V">
                <TEXT>I54V contributes resistance to each of the PIs except possibly DRV when present with other mutations.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS58">
                <TEXT>Q58E is a nonpolymorphic mutation that occurs more commonly in treated patients. It has been associated with decreased virological response to TPV but probably is associated with resistance to multiple PIs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS60">
                <TEXT>D60E is a polymorphic mutation that is slightly more common in viruses from PI-treated compared with untreated persons. It was weakly associated with a decreased virologic response to ATV in one of three retrospective analyses.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS62">
                <TEXT>I62V is a highly polymorphic mutation that is more common in PI-treated compared with untreated persons. It was weakly associated with a decreased virologic response to ATV in one of three retrospective analyses.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS63">
                <TEXT>L63P is a common polymorphism that becomes even more common in persons receiving PIs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS69">
                <TEXT>H69K is a highly polymorphic residue that was weakly associated with a decreased virologic response to TPV in the RESIST trials.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS71">
                <TEXT>A71T/V are polymorphisms that occur in 1-2% of untreated persons but which become much more frequent in persons receiving PIs. A71I is an uncommon mutation that appears to occur only with PI therapy; its significance is not known.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS73">
                <TEXT>G73S/T/C/A are selected by and appear to be associated with decreased susceptibility to most, if not all, PIs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS74A ">
                <TEXT>T74A is a polymorphic mutation more common in viruses from persons receiving PIs (particularly NFV and SQV) than in PI-naive persons.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS74SP">
                <TEXT>T74S is associated with reduced NFV susceptibility. It occasionally occurs in untreated persons. T74P is a nonpolymorphic mutation that occurs more commonly in heavily treated patients. It has been associated with decreased virological response to TPV but probably is associated with resistance to multiple PIs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS76">
                <TEXT>L76V reduces susceptibility to FPV, IDV, LPV, and DRV and increases susceptibility to SQV and ATV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS77">
                <TEXT>V77I is a common polymorphism that is associated with NFV therapy.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82A">
                <TEXT>V82A reduces susceptibility to IDV and LPV. With other mutations it is associated with reduced susceptibility to NFV, ATV, SQV, FPV, and TPV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82C">
                <TEXT>V82C is a rare mutation that occurs primarily in protease genes containing multiple other PI-resistance mutations.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82F">
                <TEXT>V82F reduces susceptibility to IDV, LPV, FPV, and DRV. With other mutations it is associated with reduced susceptibility to NFV, ATV, SQV, and TPV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82I">
                <TEXT>V82I is a polymorphism that is common in some non-B subtypes; it has little if any effect on PI susceptibility.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82L">
                <TEXT>V82L is a rare TPV-selected mutation. Its effect on other PIs has not been characterized.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82M">
                <TEXT>V82M has been shown to cause IDV resistance in subtype G viruses in which it is a common mutation. Its effect on other PIs has not been studied.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82S">
                <TEXT>V82S probably has a similar effect to V82T which reduces susceptibility to IDV, LPV, and TPV and with other mutations is associated with reduced susceptibility to NFV, ATV, FPV, and SQV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82T">
                <TEXT>V82T reduces susceptibility to IDV, LPV, and TPV. With other mutations it is associated with reduced susceptibility to NFV, ATV, FPV, and SQV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS83">
                <TEXT>N83D is a nonpolymorphic mutation that occurs more commonly in heavily treated patients. It has been associated with decreased virological response to TPV but probably is associated with resistance to multiple PIs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS84AC">
                <TEXT>I84A/C are rare mutations that like I84V appear to reduce susceptibility to each of the PIs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS84V">
                <TEXT>I84V causes intermediate/high-level resistance to ATV, FPV, IDV, NFV, SQV, and TPV, and low-level intermediate resistance to LPV and DRV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS85">
                <TEXT>I85V is a nonpolymorphic PI-selected mutation. It was weakly associated with a decreased virologic response to ATV in one of three retrospective analyses.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS88G ">
                <TEXT>N88G has not been studied but is likely to be similar to N88S which causes high-level resistance to NFV and ATV, low-level resistance to IDV, and increased susceptibility to FPV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS88S">
                <TEXT>N88S causes high-level resistance to NFV and ATV and low-level resistance to IDV; it increases susceptibility to FPV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS88T">
                <TEXT>N88T has not been studied but is likely to be similar to N88S which causes high-level resistance to NFV and ATV, low-level resistance to IDV, and increased susceptibility to FPV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS89">
                <TEXT>L89V is an uncommon nonpolymorphic PI-selected accessory mutation. It is one of the 11 mutations associated with decreased response to DRV in the POWER trials.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS90">
                <TEXT>L90M causes resistance to NFV, SQV, ATV, and IDV. When present with other mutations it also compromises the activity of FPV, LPV, and TPV. Its effect on DRV is not known.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS93L">
                <TEXT>I93L is a common polymorphism that becomes even more common in persons receiving PIs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS93M">
                <TEXT>I93M is a rare PI-associated mutation; its effect on PI susceptibility is not known.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

<!-- End the PR mutation-dependent comment strings. -->

<!-- Begin the RT mutation-dependent comment strings. -->

            <COMMENT_STRING id="RT_POS41">
                <TEXT>M41L usually occurs with T215Y. Together these mutations confer intermediate-to-high level resistance to AZT and d4T and a lower level of resistance to ddI, ABC, and TDF.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS44">
                <TEXT>E44A/D occur in patients receiving multiple NRTIs. E44D causes low-level resistance to 3TC and probably to each of the other NRTIs when present with V118I or one or more TAMs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS62">
                <TEXT>A62V is associated with multinucleoside resistance caused by Q151M; its effect in the absence of Q151M is not known.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS65N">
                <TEXT>K65N is a rare mutation that is associated with reduced susceptibility to ddI, ABC, 3TC, FTC and TDF.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS65R">
                <TEXT>K65R causes intermediate resistance to ddI, ABC, 3TC, FTC, and TDF, and low-level resistance to d4T. K65R causes AZT hypersusceptibility.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS67EG">
                <TEXT>D67N contributes some degree of resistance to each of the NRTIs except 3TC and FTC. It usually occurs with mutations at positions 70 or 215. D67E/G occur in heavily treated patients but their precise effect on NRTI susceptibility is not known.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS67N">
                <TEXT>D67N contributes some degree of resistance to each of the NRTIs except 3TC and FTC. It usually occurs with mutations at positions 70 or 215. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS67d">
                <TEXT>Amino acid deletions (d) in this region occur uncommonly and are often assigned to position 67. They occur in combination with other NRTI mutations and contribute decreased susceptibility to each of the NRTIs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS69D">
                <TEXT>T69D contributes resistance to ddI and d4T. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS69G">
                <TEXT>T69G occurs in isolates with a deletion at position 67 but its effect on NRTI susceptibility is not known.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS69NSAI">
                <TEXT>T69N/S/A/I are NRTI-selected mutations but their effect on NRTI susceptibility is not known. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS69i">
                <TEXT>Amino acid insertions (i) at this position occur in about 1%-2% of heavily treated persons. Together with TAMs, they confer high-level resistance to each of the NRTIs. Most susceptibility data are available for double amino acid insertions. However, insertions of 1 or >2 amino acids also occur.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS70E">
                <TEXT>K70E reduces TDF, ABC, DDI, and to a lesser extent 3TC and FTC susceptibility. K70E does not reduce AZT or d4T susceptibility. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS70G">
                <TEXT>K70G appears to reduce TDF, ABC, DDI, and to a lesser extent 3TC and FTC susceptibility. K70G does not reduce AZT susceptibility. Its effect on d4T susceptibility is not known.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS70N">
                <TEXT>K70N is a rare NRTI-selected variant. Its effect on drug susceptibility is not known. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS70R">
                <TEXT>K70R causes low-level AZT, d4T, and possibly TDF resistance and appears to have little if any effect on the other NRTIs. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS74I">
                <TEXT>L74I, like L74V, reduces ddI and ABC susceptibility. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS74V">
                <TEXT>L74V reduces ddI and ABC susceptibility. L74V increases AZT and TDF susceptibility. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS75I">
                <TEXT>V75I increases multinucleoside resistance caused by Q151M when present with F77L and F116Y; its effect in the absence of Q151M is not known. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS75MA">
                <TEXT>V75TM/A reduce d4T and possibly ddI susceptibility. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS75S">
                <TEXT>Like V75T, V75S may also reduce d4T and ddI susceptibility.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS75T">
                <TEXT>V75T reduces d4T and ddI susceptibility. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS77">
                <TEXT>F77L increases multinucleoside resistance caused by Q151M when present with V75I or F116Y; its effect in the absence of Q151M is not known. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS98G">
                <TEXT>A98G occurs in about 1% of NNRTI-naive persons and causes low-level NVP resistance. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS98S">
                <TEXT>A98G occurs in about 1% of NNRTI-naive persons and causes low-level NVP resistance. A98S is a common polymorphism that does not reduce NNRTI susceptibility.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS100">
                <TEXT>L100I causes intermediate resistance to NVP, DLV, and EFV, and low-resistance to ETR. It nearly always in combination with K103N.  L100I increases susceptibility to AZT and TDF.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS101E">
                <TEXT>K101E is associated with intermediate resistance to NVP and DLV and low-level resistance to EFV and ETR. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS101HN">
                <TEXT>K101H/N are NNRTI-associated mutations with uncertain phenotypic and clinical effects. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS101P">
                <TEXT>K101P usually occurs with K103N and in this setting causes high-level resistance to NVP, DLV, and EFV and low-intermediate resistance to ETR.  
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS101QR">
                <TEXT>K101Q/R occasionally occur in untreated persons and do not decrease NNRTI susceptibility. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS103N">
                <TEXT>K103N causes high-level resistance to NVP, DLV, and EFV. By itself it has no effect on ETR susceptibility. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS103Q">
                <TEXT>K103Q is a rare mutation. It has not been associated with NNRTI resistance. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS103R">
                <TEXT>K103R occurs in about 1%-2% of untreated persons and by itself has no effect on NNRTI susceptibility. However, the combination of K103R + V179D, reduces intermediate resistance to NVP, DLV, and EFV. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS103S">
                <TEXT>K103S causes high-level resistance to NVP and intermediate resistance to DLV and EFV.  
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS103TH">
                <TEXT>K103T/H are rare mutations that appear to be associated with high-level resistance to NVP, DLV, and EFV.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS106A">
                <TEXT>V106A causes high-level NVP resistance, intermediate DLV resistance, and low-level EFV and ETR resistance.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS106I">
                <TEXT>V106I is a common polymorphism that does not decrease NNRTI susceptibility. However, in a multivariate analysis it was associated with decreased ETR response in the DUET study.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS106L">
                <TEXT>V106L is a rare mutation of uncertain significance.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS106M">
                <TEXT>V106M causes high-level resistance to NVP, EFV, and DLV but does not appear to decrease ETR susceptibility.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS108">
                <TEXT>V108I causes low-level reductions in susceptibility to each of the NNRTIs except possibly ETR.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS115">
                <TEXT>Y115F causes intermediate resistance to ABC and low-level resistance to TDF.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS116">
                <TEXT>F116Y increases multinucleoside resistance caused by Q151M when present with F77L or V75I; its effect in the absence of Q151M is not known. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS118">
                <TEXT>V118I occurs in ~2% of untreated persons and with increased frequency in persons receiving multiple NRTIs. It causes low-level resistance to 3TC and possibly to other NRTIs when present with E44A/D and/or one or more TAMs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS138">
                <TEXT>E138K is selected in vitro by ETR and reduces its susceptibility by about 5-fold. E138K reduces susceptibility other NNRTIs by about 2-5 fold.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS151L">
                <TEXT>By itself, Q151M causes intermediate resistance to AZT, ddI, d4T, and ABC; and low-level resistance to TDF. With changes at the associated positions 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T, and ABC; intermediate resistance to TDF, and low-level resistance to 3TC and FTC. Q151L is a rarely observed transitional mutation that appears to precede the emergence of the Q151M.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS151M">
                <TEXT>By itself, Q151M causes intermediate resistance to AZT, ddI, d4T, and ABC; and low-level resistance to TDF. With changes at the associated positions 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T, and ABC; intermediate resistance to TDF, and low-level resistance to 3TC and FTC. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS179DE">
                <TEXT>V179D/E cause low-level reductions in susceptibility to each of the NNRTIs. V179D occurs in about 1% of untreated persons. The combination of K103R + V179D reduces the susceptibility of NVP, DLV, and EFV by about 15-fold; the combination's effect on ETR is not known.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS179F">
                <TEXT>V179F nearly always occurs in combination with Y181C. The combination of V179F + Y181C reduces ETR susceptibility >100-fold and causes low-level EFV resistance. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS179I">
                <TEXT>V179I is a common polymorphism that does not decrease NNRTI susceptibility.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS181">
                <TEXT>Y181C/I/V cause high-level resistance to NVP and DLV and low-level resistance to EFV. Y181C/I/V reduces ETR susceptibility by 5-10 fold and lays the mutational foundation for the development of higher levels of ETR resistance. Y181C increases susceptibility to AZT and TDF.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS184">
                <TEXT>M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level in vitro resistance to ddI and ABC. M184V/I increase susceptibility to AZT, TDF, and d4T.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS188C">
                <TEXT>Y188C causes high-level resistance to NVP and low-level resistance to EFV and DLV; its effect on ETR is not known.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS188H">
                <TEXT>Y188H causes low-level resistance to NVP, EFV, and DLV and has been selected in vitro by ETR. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS188L">
                <TEXT>Y188L causes high-level resistance to NVP and EFV and low-level resistance to ETR and DLV. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS190A">
                <TEXT>G190A causes high level resistance to NVP, intermediate resistance to EFV, and low-level ETR resistance. G190A increases DLV susceptibility. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS190CTV">
                <TEXT>G190C/T/V are rare mutations that cause high-level resistance to NVP and EFV and variable resistance to DLV. Their effect on ETR is not known.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS190EQ">
                <TEXT>G190E/Q cause high-level resistance to NVP and EFV and intermediate resistance to DLV. G190E + Y181C is associated with >100-fold decreased ETR susceptibility.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS190S">
                <TEXT>G190S causes high-level resistance to NVP and EFV and low-level / intermediate resistance to ETR. G190S increases DLV susceptibility.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS210FS">
                <TEXT>L210W contributes resistance to each of the NRTIs except 3TC and FTC. It usually occurs with the mutations M41L and T215Y. L210F/S occur rarely and are of unknown significance.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS210W">
                <TEXT>L210W contributes resistance to each of the NRTIs except 3TC and FTC. It usually occurs with the mutations M41L and T215Y.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS215F">
                <TEXT>T215F causes AZT and D4T resistance and reduces susceptibility to ABC, ddI, and to a lesser extent TDF.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS215SCDEIVAN">
                <TEXT>T215S/C/D/E/I/V/A/N represent transitions between wild type and the mutations Y and F. Most of these mutations do not reduce NRTI susceptibility but their presence suggests that a resistant virus may have been transmitted.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS215Y">
                <TEXT>T215Y causes AZT and D4T resistance and reduces susceptibility to ABC, ddI, and TDF particularly when it occurs in combination with M41L and L210W. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS219NR">
                <TEXT>K219N/R occur commonly in heavily NRTI-treated patients. Their effect on NRTI susceptibility is uncertain.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS219QE">
                <TEXT>K219Q/E decrease AZT and probably d4T susceptibility when present with K70R or T215Y/F but have little if any effect on the remaining NRTIs. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS225">
                <TEXT>P225H increases EFV resistance when present in combination with K103N.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS227C ">
                <TEXT>F227C is a rare mutation which has been associated with inconsistently reported levels of resistance to each of the NNRTIs particularly ETR.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS227L">
                <TEXT>F227L usually occurs in combination with V106A and in this setting is associated with high level resistance to NVP and intermediate resistance to DLV and EFV. Its effect on ETR is not known.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS230">
                <TEXT>M230L causes intermediate-to-high-level resistance to each of the NNRTIs. It has been selected in vitro by ETR and reduces ETR susceptibility by about 10-fold.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS234">
                <TEXT>234I has been selected in vitro by etravirine and it acts synergistically with Y181C to reduce etravirine susceptibility. Its clinical significance and effect on other NNRTIs is not known.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS236">
                <TEXT>P236L causes high-level DLV resistance.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS238NT">
                <TEXT>K238N/T are NNRTI-selected mutations that usually occur in combination with other NNRTI-resistance mutations and which appear to confer intermediate levels of resistance to NVP and possibly DLV and EFV. 
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS238R">
                <TEXT>K238R is a naturally occurring variant that is common in some non-B subtypes and does not reduce NNRTI susceptibility.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS318">
                <TEXT>Y318F is a rare mutation that causes high-level DLV resistance and low/intermediate NVP resistance. It usually occurs with other NNRTI-associated mutations.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS333">
                <TEXT>G333D/E are polymorphisms that occur more frequently in persons receiving NRTIs than in untreated persons. They may facilitate AZT resistance in isolates that contain M184V and multiple TAMs.
                </TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

<!-- End the RT mutation-dependent comment strings. -->
<!-- End the RT mutation-dependent comment strings. -->

	</COMMENT_DEFINITIONS>
    </DEFINITIONS>

    <DRUG>
        <NAME>DLV</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (98G => 5,
                            100I => 40, 100V => 10,
                            101EP => 30, 101HN => 15,
                            103NST => 60, 103E => 15, 103Q => 10, 
                            103R => 5,
                            106M => 60, 106A => 50, 106L => 10,
                            108I => 10,
                            138K => 20,
                            179F => 30, 179DEM => 10,
                            181CIV => 60, 181S => 30,
                            188L => 30, 188CH => 25,
                            190EQ => 15,
                            227C => 30,
                            230L => 60,
                            234I => 10,
                            236L => 60, 236S => 25,
                            238NT => 30,
                            318F => 50
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>EFV</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (98G => 5,
                            100I => 40, 100V => 10,
                            101P => 30, 101E => 15, 101HN => 10,
                            103N => 60, 103ST => 50, 103EQ => 10, 
                            103R => 5,
                            106M => 60, 106A => 25, 106L => 5,
                            108I => 10,
                            138K => 10,
                            179F => 15, 179DEM => 10,
                            181CIV => 20, 181S => 10,
                            188L => 60, 188CH => 25,
                            190CEQSTV => 60, 190A => 40,
                            225H => 30,
                            227C => 15,
                            230L => 40,
                            234I => 10,
                            238T => 15, 238N => 12,
                            318F => 12
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>NVP</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (98G => 10,
                            100I => 40, 100V => 10,
                            101EP => 30, 101HN => 15,
                            103N => 70, 103ST => 60, 103E => 15, 
                            103Q => 10, 103R => 5,
                            106AM => 60, 106L => 10,
                            108I => 10,
                            138K => 20,
                            179F => 30, 179DEM => 10,
                            181CIV => 60, 181S => 30,
                            188CL => 60, 188H => 25,
                            190ACEQSTV => 60,
                            227C => 30, 227L => 15, 227Y => 10,
                            230L => 60,
                            234I => 10,
                            238NT => 30,
                            318F => 30
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>ETR</NAME>
	<RULE>
	    <CONDITION>SELECT ATLEAST 1 FROM (90I,98G,100I,101EP,106I,179DF,181CIV,190AS)
        </CONDITION>
	    <ACTIONS>
	        <COMMENT ref="RT7" />        
	    </ACTIONS>
	</RULE>
    </DRUG>

    <DRUG>
        <NAME>3TC</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (41L => 4,
                            44AD => 5,
                            65R => 30, 65N => 15,
                            67d => 15,
                            69i => 25, 69d => 15, 69DGN => 5, 
                            69AEIS => 2,
                            70E => 15, 70G => 10,
                            75I => 5,
                            77L => 5,
                            116Y => 5,
                            118I => 5,
                            151M => 15, 151L => 10,
                            184IV => 60,
                            210W => 4,
                            215FY => 4
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>FTC</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (41L => 4,
                            44AD => 5,
                            65R => 30, 65N => 15,
                            67d => 15,
                            69i => 25, 69d => 15, 69DGN => 5, 
                            69AEIS => 2,
                            70E => 15, 70G => 10,
                            75I => 5,
                            77L => 5,
                            116Y => 5,
                            118I => 5,
                            151M => 15, 151L => 10,
                            184IV => 60,
                            210W => 4,
                            215FY => 4
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>ABC</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (41L => 12,
                            44AD => 2,
                            62V => 2,
                            65R => 30, 65N => 10,
                            67d => 25, 67GN => 8, 67EHST => 5,
                            69i => 30, 69d => 25, 69DGN => 5, 
                            69AEIS => 2,
                            70E => 25, 70G => 20,
                            74V => 30, 74I => 20,
                            75AIMST => 5, 75L => 2,
                            77L => 10,
                            115F => 25,
                            116Y => 10,
                            118I => 2,
                            151M => 40, 151L => 20,
                            184IV => 12,
                            210W => 12,
                            215(NOT TCDEFISVY) AND EXCLUDE 215T => 10, 215(NOT TCDEFISVY) => 5, 215FY => 20, 
                            215CDEISV => 10,
                            219TW => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>AZT</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (41L => 15,
                            44AD => 2,
                            62V => 2,
                            65R AND EXCLUDE 65(NOT R) => -5,
                            67d => 30, 67GN => 15, 67E => 10, 
                            67HST => 5,
                            69di => 30, 69DGN => 5, 69AEIS => 2,
                            70R => 18, 70NST => 5,
                            74V AND EXCLUDE 74(NOT V) => -5,
                            75AIMST => 5, 75L => 2,
                            77L => 10,
                            100I AND EXCLUDE 100(NOT I) => -4,
                            116Y => 10,
                            118I => 2,
                            151M => 50, 151L => 20,
                            181C AND EXCLUDE 181(NOT C) => -4,
                            184IV AND EXCLUDE 184(NOT IV) => -8,
                            210W => 15,
                            215(NOT TCDEFISVY) AND EXCLUDE 215T => 15, 215(NOT TCDEFISVY) => 7, 215FY => 35, 
                            215CDEISV => 20,
                            219ENQ => 15, 219RTW => 10,
                            333DE => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>

	<RULE>
	    <CONDITION>74VI AND EXCLUDE 74L 
                       AND SELECT ATLEAST 1 FROM (74VI, 41(NOT M), 67(NOT D), 70(NOT K), 
                                                  210(NOT L), 215(NOT T), 219(NOT K))
            </CONDITION>
	    <ACTIONS>
	        <COMMENT ref="RT3" />
	    </ACTIONS>
	</RULE>

	<RULE>
	    <CONDITION>184VI AND EXCLUDE 184M
                       AND SELECT ATLEAST 1 FROM (184VI, 41(NOT M), 67(NOT D), 70(NOT K), 
                                                  210(NOT L), 215(NOT T), 219(NOT K))
           </CONDITION>
	    <ACTIONS>
	        <COMMENT ref="RT4" />
	    </ACTIONS>
	</RULE>

	<RULE>
	    <CONDITION>100I AND EXCLUDE 100L
                       AND SELECT ATLEAST 1 FROM (100I, 41(NOT M), 67(NOT D), 70(NOT K), 
                                                  210(NOT L), 215(NOT T), 219(NOT K))
            </CONDITION>
	    <ACTIONS>
	        <COMMENT ref="RT5" />
	    </ACTIONS>
	</RULE>

	<RULE>
	    <CONDITION>181Y AND EXCLUDE 181I
                       AND SELECT ATLEAST 1 FROM (181Y, 41(NOT M), 67(NOT D), 70(NOT K), 
                                                  210(NOT L), 215(NOT T), 219(NOT K))
            </CONDITION>
	    <ACTIONS>
	        <COMMENT ref="RT6" />
	    </ACTIONS>
	</RULE>
    </DRUG>

    <DRUG>
        <NAME>D4T</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (41L => 15,
                            44AD => 2,
                            62V => 2,
                            65R => 15,
                            67d => 30, 67GN => 12, 67E => 10, 
                            67HST => 5,
                            69di => 30, 69DGN => 10, 69AEIS => 2,
                            70R => 10, 70NST => 5,
                            75T => 50, 75M => 30, 75S => 20, 
                            75A => 15, 75I => 10, 75L => 2,
                            77L => 10,
                            116Y => 10,
                            118I => 2,
                            151M => 50, 151L => 20,
                            184IV AND EXCLUDE 184(NOT IV) => -5,
                            210W => 15,
                            215(NOT TCDEFISVY) AND EXCLUDE 215T => 15, 215(NOT TCDEFISVY) => 7, 215FY => 30, 
                            215CDEISV => 20,
                            219ENQW => 10, 219RT => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>DDI</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (41L => 12,
                            44AD => 2,
                            62V => 2,
                            65R => 30, 65N => 15,
                            67d => 25, 67GN => 8, 67EHST => 5,
                            69i => 40, 69d => 25, 69DG => 20, 
                            69N => 10, 69AIS => 5, 69E => 2,
                            70EG => 25,
                            74V => 60, 74I => 30,
                            75MT => 20, 75AIS => 10, 75L => 2,
                            77L => 10,
                            116Y => 10,
                            118I => 2,
                            151M => 50, 151L => 20,
                            184IV => 5,
                            210W => 12,
                            215(NOT TCDEFISVY) AND EXCLUDE 215T => 15, 215(NOT TCDEFISVY) => 7, 215FY => 20, 
                            215CDEISV => 10,
                            219W => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>TDF</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (41L => 12,
                            44AD => 2,
                            62V => 2,
                            65R => 40, 65N => 15,
                            67d => 15, 67GHNST => 5,
                            69i => 40, 69d => 15, 69DGN => 5, 
                            69AEIS => 2,
                            70E => 25, 70G => 15, 70R => 8,
                            75AIMT => 5, 75L => 2,
                            77L => 5,
                            100I AND EXCLUDE 100(NOT I) => -4,
                            115F => 10,
                            116Y => 5,
                            118I => 2,
                            151M => 15, 151L => 10,
                            181C AND EXCLUDE 181(NOT C) => -4,
                            184IV AND EXCLUDE 184(NOT IV) => -8,
                            210W => 12,
                            215(NOT TCDEFISVY) AND EXCLUDE 215T => 10, 215(NOT TCDEFISVY) => 5, 215Y => 20, 
                            215CDEFISV => 10,
                            219W => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>FPV</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (10F => 4, 10IRVY => 2,
                            11I => 4,
                            24I => 2, 24F => 1,
                            32I => 20, 32A => 5,
                            33F => 5,
                            46IL => 12, 46V => 10,
                            47AV => 20,
                            48MV => 5,
                            50V => 50,
                            53L => 3, 53Y => 2,
                            54M => 20, 54L => 15, 54ASTV => 10,
                            71V => 3, 71I => 2, 71T => 1,
                            73ACST => 2,
                            76V => 12,
                            82AFLMST => 10, 82C => 5,
                            84AV => 35, 84C => 25,
                            88S AND EXCLUDE 88(NOT S) => -10,
                            89V => 4,
                            90M => 15
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>

    </DRUG>

    <DRUG>
        <NAME>DRV</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (10FIRVY => 2,
                            11I => 4,
                            24I => 2, 24F => 1,
                            32I => 10, 32A => 5,
                            33F => 5,
                            46ILV => 4,
                            47V => 12, 47A => 10,
                            50V => 20,
                            53L => 3, 53Y => 2,
                            54M => 12, 54L => 10, 54ASTV => 4,
                            71IV => 2, 71T => 1,
                            73ACST => 2,
                            74P => 5,
                            76V => 12,
                            82CFLMST => 6, 82A => 4,
                            84ACV => 12,
                            89V => 4,
                            90M => 6
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>

	<RULE>
	    <CONDITION>SELECT ATLEAST 1 FROM (11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V)
            </CONDITION>
	    <ACTIONS>
	        <COMMENT ref="PR1" />
	    </ACTIONS>
	</RULE>

    </DRUG>

    <DRUG>
        <NAME>IDV</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (10F => 4, 10IRVY => 2,
                            11I => 2,
                            24I => 5, 24F => 1,
                            32I => 10, 32A => 5,
                            46IL => 12, 46V => 10,
                            47AV => 5,
                            48MV => 10, 48AST => 5,
                            53L => 3, 53Y => 2,
                            54ALMSTV => 10,
                            71V => 3, 71I => 2, 71T => 1,
                            73ACST => 5,
                            76V => 12,
                            82AFST => 35, 82M => 15, 82CL => 10,
                            84AV => 25, 84C => 15,
                            88S => 10, 88DGT => 5,
                            89V => 2,
                            90M => 20
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>LPV</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (10F => 4, 10IRVY => 2,
                            11I => 2,
                            24I => 2, 24F => 1,
                            32I => 10, 32A => 5,
                            33F => 5,
                            46IL => 12, 46V => 10,
                            47A => 40, 47V => 10,
                            48MV => 10, 48AST => 5,
                            50V => 20,
                            53L => 3, 53Y => 2,
                            54LMV => 12, 54AST => 10,
                            71V => 3, 71I => 2, 71T => 1,
                            73ACST => 2,
                            76V => 8,
                            82AFST => 20, 82CLM => 10,
                            84V => 12, 84AC => 10,
                            89V => 1,
                            90M => 10
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>ATV</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (10F => 4, 10IRVY => 2,
                            11I => 2,
                            24I => 2, 24F => 1,
                            32I => 10, 32A => 5,
                            33F => 5,
                            46IL => 15, 46V => 10,
                            47AV => 5,
                            48MV => 30, 48AST => 5,
                            50L => 50,
                            53L => 3, 53Y => 2,
                            54ALMSTV => 10,
                            71V => 3, 71I => 2, 71T => 1,
                            73ACST => 5,
                            76V AND EXCLUDE 76(NOT V) => -5,
                            82FST => 20, 82A => 15, 82LM => 10, 
                            82C => 5,
                            84AV => 25, 84C => 20,
                            88S => 30, 88GT => 15, 88D => 10,
                            89V => 1,
                            90M => 20
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>TPV</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (10V => 3, 10FIRY => 2,
                            11I => 2,
                            24F => 1,
                            32I => 8, 32A => 5,
                            33F => 8,
                            35G => 2,
                            43T => 2,
                            46ILV => 8,
                            47V => 10, 47A => 5,
                            50V AND EXCLUDE 50(NOT V) => -5,
                            53L => 3, 53Y => 2,
                            54A => 15, 54V => 10, 54MST => 5,
                            58E => 5,
                            71V => 3, 71I => 2, 71T => 1,
                            73ACST => 2,
                            74P => 10,
                            76V AND EXCLUDE 76(NOT V) => -10,
                            82L => 60, 82T => 30, 82FS => 15, 
                            82ACM => 10,
                            83D => 10,
                            84ACV => 20,
                            89V => 1,
                            90M => 6
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>

	<RULE>
	    <CONDITION>SELECT ATLEAST 1 FROM (47V,54AMV,58E,74P,82LT,83D,10V,36I,43T,46L,84V,24I,50LV,54L,76V)
            </CONDITION>
	    <ACTIONS>
	        <COMMENT ref="PR2" />
	    </ACTIONS>
	</RULE>

    </DRUG>

    <DRUG>
        <NAME>NFV</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (10F => 4, 10IRVY => 2,
                            11I => 2,
                            23I => 15,
                            24I => 2, 24F => 1,
                            30N => 50,
                            32AI => 5,
                            46IL => 25, 46V => 20,
                            47AV => 5,
                            48MV => 25, 48AST => 15,
                            50V => 5,
                            53L => 3, 53Y => 2,
                            54LMSTV => 15, 54A => 10,
                            58E => 5,
                            71V => 3, 71I => 2, 71T => 1,
                            73ACST => 5,
                            74PS => 10,
                            76V => 5,
                            82AFST => 35, 82CLM => 10,
                            84A => 40, 84V => 35, 84C => 25,
                            88S => 40, 88DGT => 25,
                            89V => 4,
                            90M => 50
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>SQV</NAME>
        <RULE>
            <CONDITION>
                SCORE FROM (10F => 4, 10IRVY => 2,
                            11I => 2,
                            24I => 2, 24F => 1,
                            32AI => 5,
                            46ILV => 5,
                            47AV => 5,
                            48MV => 50, 48AST => 30,
                            53L => 3, 53Y => 2,
                            54V => 15, 54ALMST => 10,
                            71V => 3, 71I => 2, 71T => 1,
                            73CST => 10, 73A => 5,
                            74P => 2,
                            76V AND EXCLUDE 76(NOT V) => -5,
                            82AFLMST => 10, 82C => 5,
                            84A => 40, 84V => 35, 84C => 25,
                            88D => 10, 88GST => 5,
                            89V => 1,
                            90M => 35
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <MUTATION_COMMENTS>
        <GENE>
            <NAME>PR</NAME>
<!-- Begin the PR rules for mutation-dependent comment strings. -->
            <RULE>
                <CONDITION>10IVFRY</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS10" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>11I</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS11" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>13V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS13" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>16EA</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS16" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>20RMIVT</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS20" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>23I</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS23" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>24F</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS24F" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>24I</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS24I" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>30N</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS30" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>32I</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS32" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>33F</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS33F" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>33I</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS33I" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>33V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS33V" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>35G</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS35" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>36IVLT</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS36" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>43T</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS43" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>46IL</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS46IL" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>46V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS46V" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>47A</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS47A" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>47V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS47V" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>48M</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS48M" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>48V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS48V" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>50L</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS50L" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>50V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS50V" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>53LY</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS53" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>54ATS</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS54ATS" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>54L</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS54L" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>54M</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS54M" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>54V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS54V" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>58E</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS58" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>60E</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS60" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>62V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS62" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>63P</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS63" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>69K</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS69" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>71VTIL</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS71" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>73STCA</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS73" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>74A </CONDITION>
                <ACTIONS><COMMENT ref="PR_POS74A " /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>74SP</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS74SP" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>76V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS76" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>77I</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS77" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82A</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82A" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82C</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82C" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82F</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82F" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82I</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82I" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82L</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82L" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82M</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82M" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82S</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82S" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82T</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82T" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>83D</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS83" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>84AC</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS84AC" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>84V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS84V" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>85V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS85" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>88G </CONDITION>
                <ACTIONS><COMMENT ref="PR_POS88G " /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>88S</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS88S" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>88T</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS88T" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>89V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS89" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>90M</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS90" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>93L</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS93L" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>93M</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS93M" /></ACTIONS>
            </RULE>

<!-- End the PR rules for mutation-dependent comment strings. -->

        </GENE>
        <GENE>
            <NAME>RT</NAME>
<!-- Begin the RT rules for mutation-dependent comment strings. -->
            <RULE>
                <CONDITION>41L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS41" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>44DA</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS44" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>62V</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS62" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>65N</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS65N" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>65R</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS65R" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>67EG</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS67EG" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>67N</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS67N" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>67d</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS67d" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>69D</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS69D" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>69G</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS69G" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>69NSAI</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS69NSAI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>69i</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS69i" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>70E</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS70E" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>70G</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS70G" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>70N</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS70N" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>70R</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS70R" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>74I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS74I" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>74V</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS74V" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>75I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS75I" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>75MA</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS75MA" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>75S</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS75S" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>75T</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS75T" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>77L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS77" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>98G</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS98G" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>98S</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS98S" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>100I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS100" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>101E</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS101E" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>101HN</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS101HN" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>101P</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS101P" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>101QR</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS101QR" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>103N</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS103N" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>103Q</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS103Q" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>103R</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS103R" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>103S</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS103S" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>103TH</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS103TH" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>106A</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS106A" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>106I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS106I" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>106L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS106L" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>106M</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS106M" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>108I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS108" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>115F</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS115" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>116Y</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS116" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>118I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS118" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>138K</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS138" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>151L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS151L" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>151M</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS151M" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>179DE</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS179DE" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>179F</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS179F" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>179I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS179I" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>181CIV</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS181" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>184VI</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS184" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>188C</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS188C" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>188H</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS188H" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>188L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS188L" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>190A</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS190A" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>190CTV</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS190CTV" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>190EQ</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS190EQ" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>190S</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS190S" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>210FS</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS210FS" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>210W</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS210W" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>215F</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS215F" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>215SCDEIVAN</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS215SCDEIVAN" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>215Y</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS215Y" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>219NR</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS219NR" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>219QE</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS219QE" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>225H</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS225" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>227C </CONDITION>
                <ACTIONS><COMMENT ref="RT_POS227C " /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>227L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS227L" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>230L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS230" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>234I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS234" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>236L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS236" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>238NT</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS238NT" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>238R</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS238R" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>318F</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS318" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>333DE</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS333" /></ACTIONS>
            </RULE>

<!-- End the RT rules for mutation-dependent comment strings. -->
        </GENE>
    </MUTATION_COMMENTS>
</ALGORITHM>
